Literature DB >> 4086350

Chronic active hepatitis in 26 Doberman pinschers.

M A Crawford, W D Schall, R K Jensen, J B Tasker.   

Abstract

Chronic active hepatitis with increased hepatic copper concentration was diagnosed in 25 female and 1 male Doberman Pinscher dogs. Common clinical signs included polyuria/polydipsia, weight loss, anorexia, icterus, and ascites. Increased liver enzyme activities and abnormal liver function test results were the most consistent clinicopathologic changes. The dogs were assigned to 3 groups on the basis of clinical course of the disease. Group 1 dogs (n = 12) had clinical signs of advanced liver failure and died within one week. Group 2 dogs (n = 7) had less severe clinical signs of liver disease and died within one month. Group 3 dogs (n = 5) did not have clinical signs of illness or had mild clinical signs of liver disease and died 1 to 42 months after initial evaluation. One dog could not be reevaluated and another dog was alive 3 months after initial examination. Treatments consisted of supportive care for dogs in group 1, and dietary manipulations and corticosteroids for dogs in groups 2 and 3. The association of increased liver copper concentration and chronic active hepatitis is not known.

Entities:  

Mesh:

Year:  1985        PMID: 4086350

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  10 in total

1.  Chronic hepatitis: a retrospective study in 34 dogs.

Authors:  C Fuentealba; S Guest; S Haywood; B Horney
Journal:  Can Vet J       Date:  1997-06       Impact factor: 1.008

2.  Breed, age and gender distribution of dogs with chronic hepatitis in the United Kingdom.

Authors:  N H Bexfield; R J Buxton; T J Vicek; M J Day; S M Bailey; S P Haugland; L R Morrison; R W Else; F Constantino-Casas; P J Watson
Journal:  Vet J       Date:  2012-01-04       Impact factor: 2.688

3.  Chronic hepatitis in the English springer spaniel: clinical presentation, histological description and outcome.

Authors:  N H Bexfield; C Andres-Abdo; T J Scase; F Constantino-Casas; P J Watson
Journal:  Vet Rec       Date:  2011-08-18       Impact factor: 2.695

4.  Differential expression of copper-associated and oxidative stress related proteins in a new variant of copper toxicosis in Doberman pinschers.

Authors:  Bart Spee; Paul Jj Mandigers; Brigitte Arends; Peter Bode; Ted Sgam van den Ingh; Gaby Hoffmann; Jan Rothuizen; Louis C Penning
Journal:  Comp Hepatol       Date:  2005-03-24

Review 5.  The immunopathogenetic role of autoantibodies in canine autoimmune hepatitis: lessons to learn from human autoimmune hepatitis.

Authors:  Christos Liaskos; Athanasios Mavropoulos; Timoklia Orfanidou; Vassiliki Spyrou; Labrini V Athanasiou; Charalambos Billinis
Journal:  Auto Immun Highlights       Date:  2012-10-09

6.  Association of the canine ATP7A and ATP7B with hepatic copper accumulation in Dobermann dogs.

Authors:  Xiaoyan Wu; Paul J J Mandigers; Adrian L Watson; Ted S G A M van den Ingh; Peter A J Leegwater; Hille Fieten
Journal:  J Vet Intern Med       Date:  2019-06-29       Impact factor: 3.333

7.  ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs.

Authors:  Cynthia R L Webster; Sharon A Center; John M Cullen; Dominique G Penninck; Keith P Richter; David C Twedt; Penny J Watson
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

8.  Animal models of copper-associated liver disease.

Authors:  I Carmen Fuentealba; Enrique M Aburto
Journal:  Comp Hepatol       Date:  2003-04-03

9.  Antihistone Autoantibodies in Dobermans With Hepatitis.

Authors:  H Dyggve; S Meri; T Spillmann; H Jarva; M Speeti
Journal:  J Vet Intern Med       Date:  2017-09-30       Impact factor: 3.333

10.  Hepatic copper concentrations in 546 dogs (1982-2015).

Authors:  Jaimie M Strickland; John P Buchweitz; Rebecca C Smedley; Katherine J Olstad; Ryan S Schultz; N Bari Oliver; Daniel K Langlois
Journal:  J Vet Intern Med       Date:  2018-10-07       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.